公开(公告)号：US20140302016A1

公开(公告)日：2014-10-09

申请号：US14309118

申请日：2014-06-19

Applicant: UCB Pharma S.A. ,  Biogen Idec Ma Inc.

Inventor： LINDA C. BURKLY ,  JANINE L. FERRANT-ORGETTAS ,  ELLEN A. GARBER ,  YEN-MING HSU ,  LIHE SU ,  FREDERICK R. TAYLOR ,  RALPH ADAMS ,  DEREK THOMAS BROWN ,  ANDREW GEORGE POPPLEWELL ,  MARTYN KIM ROBINSON ,  ANTHONY SHOCK ,  KERRY LOUISE TYSON

IPC: C07K16/28

CPC classification number: C07K16/2875 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/71 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92

Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.

Abstract translation: 本发明提供特异性结合CD154（CD40L）蛋白的结合蛋白，包括抗体，抗体衍生物和抗体片段。 本发明还提供了嵌合，人源化或完全人抗体，抗体衍生物或抗体片段，其特异性结合包含根据SEQ ID NO：1的可变重链序列的人源化Fab片段的表位，并包含可变轻链序列 根据SEQ ID NO：2特异性结合。 本发明的CD154结合蛋白可以引起相对于第二抗-CD154抗体降低的效应子功能。 本发明的CD154结合蛋白可用于诊断和治疗方法，例如治疗和预防包括由CD154-CD40相互作用介导的不期望的免疫应答的疾病。

公开(公告)号：US08784823B2

公开(公告)日：2014-07-22

申请号：US13656922

申请日：2012-10-22

Applicant: UCB Pharma S.A. ,  Biogen Idec MA Inc.

Inventor： Linda C. Burkly ,  Janine L. Ferrant-Orgettas ,  Ellen A. Garber ,  Yen-Ming Hsu ,  Lihe Su ,  Frederick R. Taylor ,  Ralph Adams ,  Derek Thomas Brown ,  Andrew George Popplewell ,  Martyn Kim Robinson ,  Anthony Shock ,  Kerry Louise Tyson

IPC: C07K16/28 ,  A61K39/395 ,  A61P19/02 ,  A61P19/04

CPC classification number: C07K16/2875 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/71 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92

Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.

Abstract translation: 本发明提供特异性结合CD154（CD40L）蛋白的结合蛋白，包括抗体，抗体衍生物和抗体片段。 本发明还提供了嵌合，人源化或完全人抗体，抗体衍生物或抗体片段，其特异性结合包含根据SEQ ID NO：1的可变重链序列的人源化Fab片段的表位，并包含可变轻链序列 根据SEQ ID NO：2特异性结合。 本发明的CD154结合蛋白可以引起相对于第二抗-CD154抗体降低的效应子功能。 本发明的CD154结合蛋白可用于诊断和治疗方法，例如治疗和预防包括由CD154-CD40相互作用介导的不期望的免疫应答的疾病。

公开(公告)号：US20140194596A1

公开(公告)日：2014-07-10

申请号：US14101083

申请日：2013-12-09

Applicant: UCB Pharma S.A.

Inventor： David Paul Humphreys ,  Emma Dave ,  Laura Griffin ,  Sam Philip Heywood

IPC: C07K16/46

CPC classification number: C07K16/468 ,  C07K16/00 ,  C07K16/18 ,  C07K16/245 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/522 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/569 ,  C07K2317/64 ,  C07K2317/92

Abstract: The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.

Abstract translation: 本发明提供双特异性抗体融合蛋白，其包含对感兴趣的抗原具有特异性的抗体Fab或Fab'片段，所述片段与至少一种对目的第二抗原具有特异性的单结构域抗体融合。

公开(公告)号：US20140193403A1

公开(公告)日：2014-07-10

申请号：US14173613

申请日：2014-02-05

Applicant: UCB Pharma S.A.

Inventor： Thomas Allen Ceska ,  Alistar James Henry ,  Jiye Shi

IPC: C07K16/24

CPC classification number: C07K16/244 ,  C07K14/54 ,  C07K2299/00 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates neutralising epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.

Abstract translation: 本发明涉及IL-17A和IL-17F的中和表位和与这些表位结合的抗体。 本发明还涉及抗体分子的治疗用途及其制备方法。

公开(公告)号：US20140044732A1

公开(公告)日：2014-02-13

申请号：US14035053

申请日：2013-09-24

Applicant: UCB Pharma S.A.

Inventor： Ralph Adams ,  Andrew George Popplewell ,  Stephen Edward Rapecki

IPC: C07K16/24

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

公开(公告)号：US20130267689A1

公开(公告)日：2013-10-10

申请号：US13849342

申请日：2013-03-22

Applicant: UCB Pharma S.A.

Inventor： John Latham ,  David G. Winkler

IPC: C07K16/18

CPC classification number: C07K16/18 ,  C07K16/22 ,  C07K2317/56 ,  C07K2317/565

Abstract: Compositions and methods relating to sclerostin binding agents, such as antibodies and polypeptides capable of binding to sclerostin, are provided.

Abstract translation: 提供了与硬骨素结合剂（例如能够结合硬化蛋白的抗体和多肽）相关的组合物和方法。

公开(公告)号：US20240269274A1

公开(公告)日：2024-08-15

申请号：US18406593

申请日：2024-01-08

Applicant: UCB Pharma S.A.

Inventor： Martyn K. Robinson

IPC: A61K39/395 ,  A61K33/42 ,  A61K39/00 ,  A61K45/06 ,  C07K16/18 ,  C07K16/22

CPC classification number: A61K39/3955 ,  A61K33/42 ,  A61K45/06 ,  C07K16/22 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/94

Abstract: The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.

公开(公告)号：US11896667B2

公开(公告)日：2024-02-13

申请号：US17020108

申请日：2020-09-14

Applicant: UCB PHARMA, S.A.

Inventor： Martyn K. Robinson

IPC: A61K39/395 ,  C07K16/22 ,  C07K16/18 ,  A61K45/06 ,  A61K33/42 ,  A61K39/00

CPC classification number: A61K39/3955 ,  A61K33/42 ,  A61K45/06 ,  C07K16/22 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/94

Abstract: The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.

公开(公告)号：US10048253B2

公开(公告)日：2018-08-14

申请号：US14409424

申请日：2013-06-28

Applicant: UCB PHARMA S.A.

Inventor： Alastair David Griffiths Lawson ,  Alistair James Henry

IPC: G01N33/53 ,  G01N33/542 ,  C40B30/04 ,  C07K16/42 ,  G06F19/16

Abstract: The present invention relates to an improved method for drug discovery. In particular the present invention provides a method of identifying compounds capable of binding to a functional conformational state of a protein of interest or protein fragment thereof, said method comprising the steps of: (a) Binding a function-modifying antibody to the target protein of interest or a fragment thereof to provide an antibody-constrained protein or fragment, wherein the antibody has binding kinetics with the protein or fragment which are such that it has a low dissociation rate constant, (b) Providing a test compound which has a low molecular weight, (c) Evaluating whether the test compound of step b) binds the antibody constrained protein or fragment, and (d) Select a compound from step c) based on the ability to bind to the protein or fragment thereof.

公开(公告)号：US09951365B2

公开(公告)日：2018-04-24

申请号：US14400068

申请日：2013-05-13

Applicant: UCB PHARMA S.A.

Inventor： Philip Jonathan Bassett ,  David Paul Humphreys ,  Pareshkumar Manjibhai Patel

IPC: C12N15/70 ,  C12P21/00 ,  C07K16/28 ,  C12P21/02 ,  C12N9/52

CPC classification number: C12P21/00 ,  C07K16/283 ,  C07K2317/10 ,  C12N9/52 ,  C12N15/70 ,  C12P21/02

Abstract: The present disclosure relates to a recombinant gram-negative bacterial cell comprising: a.) a mutant spr gene encoding a spr protein having a mutation at one or more amino acids selected from D133, H145, H157, N31, R62, I70, Q73, C94, S95, V98, Q99, R100, L108, Y115, V135, L136, G140, R144 and G147 and b.) a gene capable of expressing or overexpressing one or more proteins capable of facilitating protein folding, such as FkpA, Skp, SurA, PPiA and PPiD, wherein the cell has reduced Tsp protein activity compared to a wild-type cell, methods employing the cells, use of the cells in the expression of proteins in particular antibodies, such as anti Fc Rn antibodies and proteins made by the methods described herein.